Interferon β for secondary progressive multiple sclerosis: A systematic review

Loredana La Mantia, Laura Vacchi, Marco Rovaris, Carlo Di Pietrantonj, George Ebers, Sten Fredrikson, Graziella Filippini

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background It is unclear whether recombinant b interferons (IFNβ) can be effective in secondary progressive multiple sclerosis (SPMS). The aim was to determine whether IFNβ can reduce the risk of disability and cognitive impairment progression in SPMS. Methods Using Cochrane methodology, we reviewed all randomised placebo controlled trials of IFNβ in SPMS patients (1995eMarch 2012). Results 5 trials (3082 patients) were included. After 3 years, interferons did not reduce disability progression, confirmed at 6 months (RR 0.98, 95% CI 0.82 to 1.16). A small reduction in the number of patients who had relapses during the first 3 years of treatment (RR 0.91, 0.84 to 0.97) was found. No analysis of cognitive data was possible. More treated than placebo patients dropped out for adverse events. Conclusion 3 year treatment with IFNβ does not delay permanent disability in SPMS but reduces relapse risk, indicating that the anti-inflammatory effect of IFNβ is unable to prevent MS progression once it has become established.

Original languageEnglish
Pages (from-to)420-426
Number of pages7
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume84
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Chronic Progressive Multiple Sclerosis
Interferons
Placebos
Recurrence
Multiple Sclerosis
Systematic Review
Anti-Inflammatory Agents
Randomized Controlled Trials
Progression
Therapeutics
Placebo
Relapse

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery
  • Arts and Humanities (miscellaneous)

Cite this

Interferon β for secondary progressive multiple sclerosis : A systematic review. / La Mantia, Loredana; Vacchi, Laura; Rovaris, Marco; Di Pietrantonj, Carlo; Ebers, George; Fredrikson, Sten; Filippini, Graziella.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 84, No. 4, 04.2013, p. 420-426.

Research output: Contribution to journalArticle

La Mantia, L, Vacchi, L, Rovaris, M, Di Pietrantonj, C, Ebers, G, Fredrikson, S & Filippini, G 2013, 'Interferon β for secondary progressive multiple sclerosis: A systematic review', Journal of Neurology, Neurosurgery and Psychiatry, vol. 84, no. 4, pp. 420-426. https://doi.org/10.1136/jnnp-2012-303291
La Mantia, Loredana ; Vacchi, Laura ; Rovaris, Marco ; Di Pietrantonj, Carlo ; Ebers, George ; Fredrikson, Sten ; Filippini, Graziella. / Interferon β for secondary progressive multiple sclerosis : A systematic review. In: Journal of Neurology, Neurosurgery and Psychiatry. 2013 ; Vol. 84, No. 4. pp. 420-426.
@article{3ec2223508cb4867a314231bd6bd6304,
title = "Interferon β for secondary progressive multiple sclerosis: A systematic review",
abstract = "Background It is unclear whether recombinant b interferons (IFNβ) can be effective in secondary progressive multiple sclerosis (SPMS). The aim was to determine whether IFNβ can reduce the risk of disability and cognitive impairment progression in SPMS. Methods Using Cochrane methodology, we reviewed all randomised placebo controlled trials of IFNβ in SPMS patients (1995eMarch 2012). Results 5 trials (3082 patients) were included. After 3 years, interferons did not reduce disability progression, confirmed at 6 months (RR 0.98, 95{\%} CI 0.82 to 1.16). A small reduction in the number of patients who had relapses during the first 3 years of treatment (RR 0.91, 0.84 to 0.97) was found. No analysis of cognitive data was possible. More treated than placebo patients dropped out for adverse events. Conclusion 3 year treatment with IFNβ does not delay permanent disability in SPMS but reduces relapse risk, indicating that the anti-inflammatory effect of IFNβ is unable to prevent MS progression once it has become established.",
author = "{La Mantia}, Loredana and Laura Vacchi and Marco Rovaris and {Di Pietrantonj}, Carlo and George Ebers and Sten Fredrikson and Graziella Filippini",
year = "2013",
month = "4",
doi = "10.1136/jnnp-2012-303291",
language = "English",
volume = "84",
pages = "420--426",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Interferon β for secondary progressive multiple sclerosis

T2 - A systematic review

AU - La Mantia, Loredana

AU - Vacchi, Laura

AU - Rovaris, Marco

AU - Di Pietrantonj, Carlo

AU - Ebers, George

AU - Fredrikson, Sten

AU - Filippini, Graziella

PY - 2013/4

Y1 - 2013/4

N2 - Background It is unclear whether recombinant b interferons (IFNβ) can be effective in secondary progressive multiple sclerosis (SPMS). The aim was to determine whether IFNβ can reduce the risk of disability and cognitive impairment progression in SPMS. Methods Using Cochrane methodology, we reviewed all randomised placebo controlled trials of IFNβ in SPMS patients (1995eMarch 2012). Results 5 trials (3082 patients) were included. After 3 years, interferons did not reduce disability progression, confirmed at 6 months (RR 0.98, 95% CI 0.82 to 1.16). A small reduction in the number of patients who had relapses during the first 3 years of treatment (RR 0.91, 0.84 to 0.97) was found. No analysis of cognitive data was possible. More treated than placebo patients dropped out for adverse events. Conclusion 3 year treatment with IFNβ does not delay permanent disability in SPMS but reduces relapse risk, indicating that the anti-inflammatory effect of IFNβ is unable to prevent MS progression once it has become established.

AB - Background It is unclear whether recombinant b interferons (IFNβ) can be effective in secondary progressive multiple sclerosis (SPMS). The aim was to determine whether IFNβ can reduce the risk of disability and cognitive impairment progression in SPMS. Methods Using Cochrane methodology, we reviewed all randomised placebo controlled trials of IFNβ in SPMS patients (1995eMarch 2012). Results 5 trials (3082 patients) were included. After 3 years, interferons did not reduce disability progression, confirmed at 6 months (RR 0.98, 95% CI 0.82 to 1.16). A small reduction in the number of patients who had relapses during the first 3 years of treatment (RR 0.91, 0.84 to 0.97) was found. No analysis of cognitive data was possible. More treated than placebo patients dropped out for adverse events. Conclusion 3 year treatment with IFNβ does not delay permanent disability in SPMS but reduces relapse risk, indicating that the anti-inflammatory effect of IFNβ is unable to prevent MS progression once it has become established.

UR - http://www.scopus.com/inward/record.url?scp=84875215923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875215923&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2012-303291

DO - 10.1136/jnnp-2012-303291

M3 - Article

C2 - 22952326

AN - SCOPUS:84875215923

VL - 84

SP - 420

EP - 426

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 4

ER -